Atlas Trials

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Clinical trial NCT04720131 · COMPLETED

Trial details

NCT number
NCT04720131
Sponsor
Beijing Friendship Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract CancerAnti-PD-1 TherapyTargeted Molecular TherapyCapecitabine
Start date
2021-01-01
Primary completion
2023-04-30
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.